Thyroid carcinoma

Lancet

Volumn 361, Issue 9356, 2003, Pages 501-511

  Sherman, Steven I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FUMAGILLOL CHLOROACETYLCARBAMATE; IODINE 131; OCTREOTIDE; PACLITAXEL; RADIOACTIVE IODINE; TAMOXIFEN; THYROID HORMONE; THYROTROPIN;

ANAPLASTIC CARCINOMA; ASPIRATION BIOPSY; BEAM THERAPY; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL DIFFERENTIATION; CHROMOSOME REARRANGEMENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CYTODIAGNOSIS; DIAGNOSTIC PROCEDURE; DRUG MEGADOSE; DRUG UPTAKE; EARLY DIAGNOSIS; ECHOGRAPHY; EDEMA; GENETIC ANALYSIS; GENETIC DISORDER; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; HYPOTHYROIDISM; LUNG FIBROSIS; MALIGNANT TRANSFORMATION; MEDICAL DECISION MAKING; MEDLINE; META ANALYSIS; METASTASIS; MULTIMODALITY CANCER THERAPY; OLIGOSPERMIA; OVARY INSUFFICIENCY; PATIENT EDUCATION; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RADIATION CARCINOGENESIS; RADIATION DOSE; RADIATION EXPOSURE; SIALOADENITIS; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; THYROIDITIS; TOXICITY; TUMOR BLEEDING;

EID: 0037425748     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12488-9     Document Type: Conference Paper

References (168)

1. Figge J. Epidemiology of thyroid cancer. Wartofsky L. Thyroid Cancer: a comprehensive guide to clinical management. 1999;77-83 Humana Press, Totowa.
2. Gilliland F.D., Hunt W.C., Morris D.M., Key C.R. Prognostic factors for thyroid carcinoma: A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer. 79:1997;564-573.
3. Teppo L., Hakulinen T. Eurocare Working Group. Variation in survival of adult patients with thyroid cancer in Europe. Eur J Cancer. 34:1998;2248-2252.
4. Maldonado MR, Sherman SI. Predictive value of clinicopathologic staging for medullary thyroid carcinoma. 72nd Annual Meeting of the American Thyroid Association; 1999; Palm Beach, FL, 1999.
5. Dinneen S.F., Valimaki M.J., Bergstralh E.J., et al. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab. 80:1995;2041-2045.
6. Kumar H., Daykin J., Holder R., et al. An audit of management of differentiated thyroid cancer in specialist and non-specialist clinic settings. Clin Endocrinol (Oxf). 54:(6):2001;719-723.
7. British Thyroid Association and Royal College of Physicians. Guidelines for the management of thyroid cancer in adults London: Guidelines for the management of thyroid cancer in adults, 2002.
8. AACE/AAES medical/surgical guidelines for clinical practice: Management of thyroid carcinoma. Endocr Pr. 7:2001;203-220.
9. Sherman SI. NCCN practice guidelines for thyroid cancer, version 2001. National Comprehensive Cancer Network, 2001.
10. Brandi ML, Gagel RF, Angeli A, et al. Jr., Marx SJ. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658-71.
11. Singer P.A., Cooper D.S., Daniels G.H., et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med. 156:1996;2165-2172.
12. Ravetto C., Colombo L., Dottorini M.E. Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma: a retrospective study in 37,895 patients. Cancer. 90:2000;357-363.
13. Gharib H., Goellner J.R. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med. 118:(4):1993;282-289.
14. Baloch Z.W., Fleisher S., LiVolsi V.A., Gupta P.K. Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol. 26:2002;41-44.
15. Tyler D.S., Winchester D.J., Caraway N.P., Hickey R.C., Evans D.B. Indeterminate fine-needle aspiration biopsy of the thyroid. Identification of subgroups at high risk for invasive carcinoma. Surgery. 116:(12):1994;1054-1060.
16. Tuttle R.M., Lemar H., Burch H.B. Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by fine-needle aspiration. Thyroid. 8:1998;377-383.
17. Bartolazzi A., Gasbarri A., Papotti M., et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 357:2001;1644-1650.
18. Udelsman R., Westra W.H., Donovan P.I., Sohn T.A., Cameron J.L. Randomized prospective evaluation of frozen-section analysis for follicular neoplasms of the thyroid. Ann Surg. 23:2001;716-722.
19. Roach J.C., Heller K.S., Dubner S., Sznyter L.A. The value of frozen section examinations in determining the extent of thyroid surgery in patients with indeterminate fine-needle aspiration cytology. Arch Otolaryngol Head Neck Surg. 128:2002;263-267.
20. Cramer H. Fine-needle aspiration cytology of the thyroid: an appraisal. Cancer. 90:2000;325-329.
21. Cases J.A., Surks M.I. The changing role of scintigraphy in the evaluation of thyroid nodules. Semin Nucl Med. 30:2000;81-87.
22. Ezzat S., Sarti D.A., Cain D.R., Braunstein G.D. Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Arch Intern Med. 154:1994;1838-1840.
23. Burguera B., Gharib H. Thyroid incidentalomas. Prevalence, diagnosis, significance, and management. Endocrinol Metab Clin North Am. 29:2000;187-203.
24. Tan G.H., Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med. 126:1997;226-231.
25. Figge J., Jennings T., Gerasimov G. Radiation and thyroid cancer. Wartofsky L. Thyroid cancer: a comprehensive guide to clinical management. 1999;85-116 Humana Press, Totowa.
26. Pacini F., Vorontsova T., Demidchik E.P., et al. Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab. 82:1997;3563-3569.
27. Musholt T.J., Musholt P.B., Petrich T., et al. Familial papillary thyroid carcinoma: genetics, criteria for diagnosis, clinical features, and surgical treatment. World J Surg. 24:2000;1409-1417.
28. Alsanea O., Wada N., Ain K., et al. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery. 128:2000;1043-1050.
29. McKay J.D., Lesueur F., Jonard L., et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet. 69:2001;440-446.
30. Fagin J.A. Molecular pathogenesis of tumors of thyroid follicular cells. Fagin J.A. Thyroid Cancer. 1998;Kluwer, Boston.
31. Nikiforova M.N., Stringer J.R., Blough R., et al. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science. 290:2000;138-141.
32. Elisei R., Shiohara M., Koeffler H.P., Fagin J.A. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer. 83:1998;2185-2193.
33. Ouyang B., Knauf J.A., Ain K., Nacev B., Fagin J.A. Mechanisms of aneuploidy in thyroid cancer cell lines and tissues: evidence for mitotic checkpoint dysfunction without mutations in BUB1 and BUBR1. Clin Endocrinol (Oxf). 56:2002;341-350.
34. Specht M.C., Barden C.B., Fahey T.J. 3rd. p44/p42-MAP kinase expression in papillary thyroid carcinomas. Surgery. 130:2001;936-940.
35. Saavedra H.I., Knauf J.A., Shirokawa J.M., et al. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene. 19:2000;3948-3954.
36. Kroll T.G., Sarraf P., Pecciarini L., et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science. 289:2000;1357-1360.
37. Minireview FJA. branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol 2002; 16: 903-11.
38. Byar D.P., Green S.B., Dor P., et al. A prognostic index for thyroid carcinoma. A study of the E O R T C thyroid cancer cooperative group. Eur J Cancer. 15:1979;1033-1041.
39. Cady B., Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 104:1988;947-953.
40. Hermanek P, Sobin LH. TNM Classification of Malignant Tumours. 4th edn, 2nd rev edn. Berlin: Springer, 1992.
41. Hay I.D., Grant C.S., Taylor W.F., McConahey W.M. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 102:1987;1088-1095.
42. Hay I.D., Bergstralh E.J., Goellner J., Ebersold J.R., Grant C.S. Predicting outcome in papillary carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients treated surgically at one institution during 1940 through 1989. Surgery. 114:1993;1050-1058.
43. DeGroot L.J., Kaplan E.L., McCormick M., Straus F.H. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 71:1990;414-424.
44. Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 97:1994;418-428.
45. Sherman S.I., Brierley J.D., Sperling M., et al. HR. Prospective multicenter study of treatment of thyroid carcinoma: initial analysis of staging and outcome. Cancer. 83:1998;1012-1021.
46. Brierley J.D., Panzarella T., Tsang R.W., Gospodarowicz M.K., O'Sullivan B. A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer. 79:1997;2414-2423.
47. Sherman S.I. Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma. Semin Surg Oncol. 16:(1):1999;12-15.
48. Recommended reporting format for thyroid carcinoma. Am J Clin Pathol. 11:(5):2000;684-686.
49. Burman K.D., Ringel M.D., Wartofsky L. Unusual types of thyroid neoplasms. Endocrinol Metab Clin North Am. 25:1996;49-68.
50. Katoh R., Sasaki J., Kurihara H., et al. Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients. Cancer. 70:1992;1585-1590.
51. Silverberg S.G., Hutter R.V.P., Foote F.W. Jr. Fatal carcinoma of the thyroid: histology, metastases, and causes of death. Cancer. 25:1970;792-802.
52. Hay I.D., Grant C.S., Bergstralh E.J., Thompson G.B., van Heerden J.A., Goellner J.R. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery. 124:1998;958-966.
53. Taylor T., Specker B., Robbins J., et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med. 129:1998;622-627.
54. DeGroot L.J., Kaplan E.L., Straus F.H. Does the method of management of papillary thyroid carcinoma make a difference in outcome? World J Surg. 18:1994;123-130.
55. Samaan N.A., Schultz P.N., Hickey R.C., et al. The results of various modalities of treatment of well differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab. 75:1992;714-720.
56. Cady B. Papillary carcinoma of the thyroid gland: treatment based on risk group definition. Surg Oncol Clin N Am. 7:1998;633-644.
57. Shaha A.R., Shah J.P., Loree T.R. Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol. 4:1997;328-333.
58. Sherman S.I. The risks of thyroidectomy: words of caution for referring physicians. J Gen Intern Med. 13:1998;60-61.
59. Grant C.S. Operative and postoperative management of the patient with follicular and Hurthle cell carcinoma. Surg Clin N Am. 75:1995;395-403.
60. Grebe S.K., Hay I.D. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 5:1996;43-63.
61. Vassilopoulou-Sellin R., Schultz P.N., Haynie T.P. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer. 78:1996;493-501.
62. Simon D., Goretzki P.E., Witte J., Roher H.D. Incidence of regional recurrence guiding radicality in differentiated thyroid carcinoma. World J Surg. 20:1996;860-866.
63. Gillenwater A.M., Goepfert H. Surgical management of laryngotracheal and esophageal involvement by locally advanced thyroid cancer. Semin Surg Oncol. 16:1999;19-29.
64. Catz B., Petit D., Schwartz M., Davis F., McCammon C., Starr P. Treatment of cancer of the thyroid postoperatively with suppressive thyroid medication, radioiodine, and thyroid-stimulating hormone. Cancer. 12:1959;371-383.
65. Maxon H.R., Thomas S.R., Samaratunga R.C. Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid. 7:1997;183-188.
66. Wong J.B., Kaplan M.M., Meyer K.B., Pauker S.G. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma: a decision analytic perspective. Endocrinol Metab Clin North Am. 19:1990;741-760.
67. Schlumberger M., Tubiana M., De Vathaire F., et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab. 63:1986;960-967.
68. 131I uptake post-thyroidectomy for thyroid cancer. J Clin Endocrinol Metab. 50:1980;734-739.
69. Lakshmanan M., Schaffer A., Robbins J., Reynolds J., Norton J. A simplified low iodine diet in I-131 scanning and therapy of thyroid cancer. Clin Nucl Med. 13:1988;866-868.
70. Sherman S.I., Tielens E.T., Sostre S., Wharam M.D. Jr, Ladenson P.W. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab. 78:1994;629-634.
71. Muratet J.P., Daver A., Minier J.F., Larra F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med. 39:1998;1546-1550.
72. Mandel S.J., Shankar L.K., Benard F., Yamamoto A., Alavi A. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med. 26:2001;6-9.
73. Logue J.P., Tsang R.W., Brierley J.D., Simpson W.J. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome. Br J Radiol. 67:1994;1127-1131.
74. Bal C., Padhy A.K., Jana S., Pant G.S., Basu A.K. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer. 77:1996;2574-2580.
75. Beierwaltes W.H., Rabbani R., Dmuchowski C., Lloyd R.V., Eyre P., Mallette S. An analysis of ablation of thyroid remnants with I-131 in 511 patients from 1947-1984: Experience at University of Michigan. J Nucl Med. 25:1984;1287-1293.
76. Maxon H.R., Englaro E.E., Thomas S.R., et al. Radioiodine-131 therapy for well-differentiated thyroid cancer - a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med. 33:1992;1132-1136.
77. Reynolds J.C. Percent 131I uptake and post-therapy 131I scans: their role in the management of thyroid cancer. Thyroid. 7:1997;281-284.
78. Pujol P., Daures J.-P., Nsakala N., Baldet L., Bringer J., Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab. 81:1996;4318-4323.
79. Cooper D.S., Specker B., Ho M., et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid. 8:1998;737-744.
80. Stall G.M., Harris S., Sokoll L.J., Dawson-Hughes B. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxinek. Ann Intern Med. 113:1990;265-269.
81. Bauer D.C., Ettinger B., Nevitt M.C., Stone K.L. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med. 134:2001;561-568.
82. Sawin C.T., Geller A., Wolf P.A., et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 331:1994;1249-1252.
83. Biondi B., Palmieri E.A., Fazio S., et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle aged patients. J Clin Endocrinol Metab. 85:2000;4701-4705.
84. Tsang R.W., Brierley J.D., Simpson W.J., Panzarella T., Gospodarowicz M.K., Sutcliffe S.B. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer. 82:1998;375-388.
85. Farahati J., Reiners C., Stuschke M., et al. Differentiated thyroid cancer. impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer. 77:1996;172-180.
86. Brierley J.D., Tsang R.W. External-beam radiation therapy in the treatment of differentiated thyroid cancer. Semin Surg Oncol. 16:1999;42-49.
87. Grigsby P.W., Baglan K., Siegel B.A. Surveillance of patients to detect recurrent thyroid carcinoma. Cancer. 85:1999;945-951.
88. Antonelli A., Miccoli P., Fedeghini M., et al. Role of neck ultrasound in the follow-up of patients operated on for thyroid cancer. Thyroid. 5:1995;25-28.
89. Krishnamurthy S., Bedi D.G., Caraway N.P. Ultrasound-guided fine-needle aspiration biopsy of the thyroid bed. Cancer (Cytopathology). 93:2001;199-205.
90. Franceschi M., Kusic Z., Franceschi D., Lukinac L., Roncevic S. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med. 37:1996;446-451.
91. Frilling A., Gorges R., Tecklenborg K., Gassmann P., et al. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery. 128:2000;1067-1074.
92. Shiga T., Tsukamoto E., Nakada K. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med. 42:2001;414-419.
93. Spencer C.A., LoPresti J.S., Fatemi S., Nicoloff J.T. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid. 9:1999;435-441.
94. Ozata M., Suzuki S., Miyamoto T., Liu R.T., Fierro-Renoy F., DeGroot L.J. Serum thyroglobulin in the follow-up of patients treated with differentiated thyroid cancer. J Clin Endocrinol Metab. 79:1994;98-105.
95. Schlumberger M., Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol. 138:1998;249-252.
96. Mueller-Gaertner H.W., Schneider C. Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer. Cancer. 61:1988;976-981.
97. Haugen B.R., Pacini F., Reiners C., et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 84:1999;3877-3885.
98. Mariotti S., Barbesino G., Caturegli P., et al. Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal? J Clin Endocrinol Metab. 80:1995;468-472.
99. Spencer C.A., Takeuchi M., Kazarosyan M. Current status and performance goals for thyroglobulin assays. Clin Chem. 42:1996;164-173.
100. Hollowell J.G., Staehling N.W., Flanders W.D., et al. Serum TSH, T(4), and thyroid antibodies in the United States population1988: National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 87:2002;489-499.
101. Spencer C.A., Takeuchi M., Kazarosyan M., et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 83:1998;1121-1127.
102. Ringel M.D., Ladenson P.W., Levine M.A. Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. J Clin Endocrinol Metab. 83:1998;4435-4442.
103. Takano T., Miyauchi A., Yoshida H., Hasegawa Y., Kuma K., Amino N. Quantitative measurement of thyroglobulin mRNA in peripheral blood of patients after total thyroidectomy. Br J Cancer. 85:2001;102-106.
104. Ladenson P.W. Strategies for thyrotropin use to monitor patients with treated thyroid carcinoma. Thyroid. 9:1999;429-433.
105. Pacini F., Lippi F. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): serum thyroglobulin measurement. J Endocrinol Invest. 22:1999;25-29.
106. Schlumberger M., Ricard M., Pacini F. Clinical use of recombinant human TSH in thyroid cancer patients. Eur J Endocrinol. 143:2000;557-563.
107. Mazzaferri E.L., Kloos R.T. Is diagnostic Iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab. 87:2002;1490-1498.
108. Sherman SI, Lopez-Penabad L. The use of recombinant human thyrotropin in the management of thyroid carcinoma and other disorders. In: Meikle AW, ed. Hormone replacement therapy, 2nd edn. Totowa NJ: Humana Press (in press).
109. Niederle B., Roka R., Schemper M., Fritsch A., Weissel M., Ramach W. Surgical treatment of distant metastases in differentiated thyroid cancer: indication and results. Surgery. 100:1986;1088-1097.
110. Chiu A.C., Delpassand E.S., Sherman S.I. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab. 82:1997;3637-3642.
111. Bernier M.O., Leenhardt L., Hoang C., et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab. 86:2001;1568-1573.
112. Beierwaltes W.H., Nishiyama R.H., Thompson N.W., Copp J.E., Kubo A. Survival time and "cure" in papillary and follicular thyroid carcinoma with distant metastases: statistics following University of Michigan therapy. J Nucl Med. 23:1982;561-568.
113. Brierley J., Maxon H.R. Radioiodine and external radiation therapy in the treatment of thyroid cancer. Fagin J.A. Thyroid cancer. 1998;285-317 Kluwer Academic Publishers, Boston.
114. Maxon H.R., Smith H.S. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am. 19:1990;685-718.
115. Sisson J.C., Giordano T.J., Jamadar D.A., et al. 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer. 78:1996;2184-2192.
116. Furhang E.E., Larson S.M., Buranapong P., Humm J.L. Thyroid cancer dosimetry using clearance fitting. J Nucl Med. 40:1999;131-136.
117. Vassilopoulou-Sellin R., Palmer L., Taylor S., Cooksley C.S. Incidence of breast carcinoma in women with thyroid carcinoma. Cancer. 85:1999;696-705.
118. de Vathaire F., Schlumberger M., Delisle M.J., et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer. 75:1997;734-739.
119. Chen A.Y., Levy L., Goepfert H., Brown B.W., Spitz M.R., Vassilopoulou-Sellin R. The development of breast carcinoma in women with thyroid carcinoma. Cancer. 92:2001;225-231.
120. Pacini F., Gasperi M., Fugazzola L., et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med. 35:1994;1418-1422.
121. Vini L., Hyer S., Al-Saadi A., Pratt B., Harmer C. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J. 78:2002;92-93.
122. Ceccarelli C., Bencivelli W., Morciano D., Pinchera A., Pacini F. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab. 86:2001;3512-3515.
123. Haugen B.R. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol. 16:1999;34-41.
124. Vassilopoulou-Sellin R., Goepfert H., Raney B., Schultz P.N. Differentiated thyroid cancer in children and adolescents: clinical outcome and mortality after long-term follow-up. Head Neck. 20:1998;549-555.
125. Ball D.W., Baylin S.B., de Bustros A.C. Medullary thyroid carcinoma. Braverman L.E., Utiger R.D. Werner and Ingbars: the thyroid. 7th edn: 1996;946-960 Lippincott-Raven, Philadelphia.
126. Horvit P.K., Gagel R.F. Editorial: The goitrous patient with an elevated serum calcitonin - what to do? J Clin Endocrinol Metab. 82:1997;335-337.
127. Hahm J.R., Lee M.S., Min Y.K., et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid. 11:2001;73-80.
128. Bennedbaek F.N., Perrild H., Hegedus L. Diagnosis and treatment of the solitary thyroid nodule: results of a European survey. Clin Endocrinol (Oxf). 50:1999;357-363.
129. Redding A.H., Levine S.N., Fowler M.R. Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses. Thyroid. 10:2000;919-922.
130. Gagel R.F., Cote G.J. Pathogenesis of medullary thyroid carcinoma. Fagin J.A. Thyroid cancer. 1998;85-103 Kluwer Academic Publishers, Boston.
131. Ponder B.A., Ponder M.A., Coffey R., et al. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet. 1:1988;397-401.
132. Niccoli-Sire P., Murat A., Rohmer V., et al. Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients. J Clin Endocrinol Metab. 86:2001;3746-3753.
133. Hansford J.R., Mulligan L.M. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet. 37:2000;817-827.
134. Wohllk N., Cote G.J., Bugalho M.M.J., et al. Relevence of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab. 81:1996;3740-3745.
135. Freyer G., Ligneau B., Schlumberger M., et al. Quality of life in patients at risk of medullary thyroid carcinoma and followed by a comprehensive medical network: trends for future evaluations. Ann Oncol. 12:2001;1461-1465.
136. Saad M.F., Ordonez N.G., Rashid R.K., Guido J.J., Hill J.C.S., Hickey R.C., Samaan N.A. Medullary carcinoma of the thyroid. Medicine. 63:1984;319-342.
137. O'Riordain D.S., O'Brien T., Weaver A.L., Gharib H., Hay I.D., Grant C.S., van Heerden J.A. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery. 116:1994;1017-1023.
138. Hyer S.L., Vini L., A'Hern R., Harmer C. Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol. 26:2000;686-690.
139. Saad M.F., Guido J.J., Samaan N.A. Radioactive iodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab. 57:1983;124-128.
140. Brierley J., Tsang R., Simpson W.J., Gospodarowicz M., Sutcliffe S., Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid. 6:1996;305-310.
141. Pacini F., Basolo F., Elisei R., Fugazzola L., Cola A., Pinchera A. Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens. Am J Clin Pathol. 95:1991;300-308.
142. Fugazzola L., Pinchera A., Luchetti F., et al. Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers. 9:1994;21-24.
143. Orlandi F., Caraci P., Mussa A., Saggiorato E., Pancani G., Angeli A. Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer. 8:2001;135-147.
144. Abdelmoumene N., Schlumberger M., Gardet P., et al. Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma. Br J Cancer. 69:1994;1141-1144.
145. van Heerden J.A., Grant C.S., Gharib H., Hay I.D., Ilstrup D.M. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg. 212:1990;395-401.
146. Dottorini M.E., Assi A., Sironi M., Sangalli G., Spreafico G., Colombo L. Multivariate analysis of patients with medullary thyroid carcinoma: prognostic significance and impact on treatment of clinical and pathologic variables. Cancer. 77:1996;1556-1565.
147. Scopsi L., Sampietro G., Boracchi P., et al. Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid: a retrospective study of 109 consecutive patients. Cancer. 78:1996;2173-2183.
148. Tisell L.E., Hansson G., Jansson S., Salander H. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery. 99:1986;60-66.
149. Moley J.F., Debenedetti M.K., Dilley W.G., Tisell L.E., Wells S.A. Surgical management of patients with persistent or recurrent medullary thyroid cancer. J Intern Med. 243:1998;521-526.
150. Fleming J.B., Lee J.E., Bouvet M., et al. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg. 230:1999;697-707.
151. Wells S.A. Jr, Skinner M.A. Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Exp Clin Endocrinol Diabetes. 106:1998;29-34.
152. Chi D.D., Moley J.F. Medullary thyroid carcinoma: genetic advances, treatment recommendations, and the approach to the patient with persistent hypercalcitoninemia. Surg Oncol Clin N Am. 7:1998;681-706.
153. Evans D.B., Fleming J.B., Lee J.E., Cote G., Gagel R.F. The surgical treatment of medullary thyroid carcinoma. Semin Surg Oncol. 16:1999;50-63.
154. Machens A., Gimm O., Hinze R., Hoppner W., Boehm B.O., Dralle H. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab. 86:2001;1104-1109.
155. Pierie J.P., Muzikansky A., Gaz R.D., Faquin W.C., Ott M.J. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol. 9:2002;57-64.
156. Xu G., Pan J., Martin C., Yeung S.C. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab. 86:2001;1769-1777.
157. McIver B., Hay I.D., Giuffrida D.F., et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery. 130:2001;1028-1034.
158. Haigh P.I., Ituarte P.H.G., Wu H.S., et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer. 91:2001;2335-2342.
159. Passler C., Scheuba C., Prager G., et al. Anaplastic (undifferentiated) thyroid carcinoma (ATC). A retrospective analysis. Langenbecks Arch Surg. 384:1999;284-293.
160. Hundahl S.A., Fleming I.D., Fremgen A.M., Menck H.R. A national cancer data base report on 53 856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer. 83:1998;2638-2648.
161. Moretti F., Farsetti A., Soddu S., et al. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene. 14:1997;729-740.
162. Sherman S.I. Anaplastic carcinoma: clinical aspects. Wartofsky L. Thyroid cancer. a comprehensive guide to clinical management. 1999;319-325 Humana Press, Totowa, NJ.
163. Takashima S., Morimoto S., Ikezoe J., et al. CT evaluation of anaplastic thyroid carcinoma. AJR Am J Roentgenol. 154:1990;1079-1085.
164. Sugitani I., Kasai N., Fujimoto Y., Yanagisawa A. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg. 25:2001;617-622.
165. Venkatesh Y.S.S., Ordonez N.G., Schultz P.N., Hickey R.C., Goepfert H., Samaan N.A. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 121 cases. Cancer. 66:1990;321-330.
166. Junor E.J., Paul J., Reed N.S. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol. 18:1992;83-88.
167. Kim J.H., Leeper R.D. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer. 60:1987;2372-2375.
168. Ain K.B., Egorin M.J., DeSimone P.A. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using 96-hour infusion. Thyroid. 10:2000;587-594.